Sarcolemmal fatty acid uptake vs. mitochondrial β-oxidation as target to regress cardiac insulin resistance

Applied Physiology, Nutrition and Metabolism

Volumn 34, Issue 3, 2009, Pages 473-480

  Luiken, Joost J F P ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cardiac insulin resistance; Carnitine palmitoyltransferase I; CD36; FABPpm; Long chain fatty acid oxidation; Long chain fatty acid uptake

Indexed keywords

FATTY ACID;

HEART MUSCLE; HUMAN; INSULIN RESISTANCE; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; PHYSIOLOGY; REVIEW; SARCOLEMMA;

FATTY ACIDS; HUMANS; INSULIN RESISTANCE; MITOCHONDRIA; MYOCARDIUM; OXIDATION-REDUCTION; SARCOLEMMA;

EID: 67651216388     PISSN: 17155312     EISSN: None     Source Type: Journal    
DOI: 10.1139/H09-040     Document Type: Review

References (46)

1. Ashrafian, H., Frenneaux, M.P., and Opie, L.H. 2007. Metabolic mechanisms in heart failure. Circulation, 116: 434-448. doi:10. 1161/CIRCULATIONAHA.107.702795. PMID:17646594.
2. Awan, M.M., and Saggerson, E.D. 1993. Malonyl-CoA metabolism in cardiac myocytes and its relevance to the control of fatty acid oxidation. Biochem. J. 295: 61-66. PMID:8216240.
3. Bassingthwaighte, J.B., Noodleman, L., van der Vusse, G.J., and Glatz, J.F.C. 1989. Modeling of palmitate transport in the heart. Mol. Cell. Biochem. 88: 51-58. doi:10.1007/BF00223423. PMID:2674667.
4. Bonen, A., Campbell, S.E., Benton, C.R., Chabowski, A., Coort, S.L.M., Han, X.X., et al. 2004. Regulation of fatty acid transport by fatty acid translocase/CD36. Proc. Nutr. Soc. 63: 245-249. doi:10.1079/PNS2004331. PMID:15294038.
5. Bonen, A., Han, X.X., Habets, D.D., Febbraio, M., Glatz, J.F.C., and Luiken, J.J.F.P. 2007. A null mutation in skeletal muscle FAT/CD36 reveals its essential role in insulin- and AICARstimulated fatty acid metabolism. Am. J. Physiol. Endocrinol. Metab. 292: E1740-E1749. doi:10.1152/ajpendo.00579.2006. PMID:17264223.
6. Buckingham, R.E., and Hanna, A. 2008. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? Diabetes Obes. Metab. 10: 312-328. doi:10.1111/j.1463-1326.2006.00700.x. PMID: 18333890.
7. Carley, A.N., and Severson, D.L. 2005. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim. Biophys. Acta, 1734: 112-126. PMID:15904868.
8. Carley, A.N., Atkinson, L.L., Bonen, A., Harper, M.E., Kunnathu, S., Lopaschuk, G.D., and Severson, D.L. 2007. Mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db/db mice. Arch. Physiol. Biochem. 113: 65-75. doi:10.1080/13813450701422617. PMID:17558605.
9. Chabowski, A., Gorski, J., Luiken, J.J.F.P., Glatz, J.F.C., and Bonen, A. 2007. Evidence for concerted action of FAT/CD36 and FABPpm to increase plasmalemmal fatty acid transport in the heart. Prostaglandins Leukot. Essent. Fatty Acids, 77: 345-353. doi:10.1016/j.plefa.2007.10.017. PMID:18240411.
10. Coort, S.L.M., Hasselbaink, D.M., Koonen, D.P.Y., Willems, J., Coumans, W.A., Chabowski, A., et al. 2004. Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats. Diabetes, 53: 1655-1663. doi:10.2337/diabetes.53.7.1655. PMID:15220187.
11. Coort, S.L.M., Coumans, W.A., Bonen, A., van der Vusse, G.J., Glatz, J.F.C., and Luiken, J.J.F.P. 2005. Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats. J. Lipid Res. 46: 1295-1302. doi:10.1194/jlr.M400426-JLR200. PMID:15772429.
12. Cushman, S.W., Goodyear, L.J., Pilch, P.F., Ralston, E., Galbo, H., Ploug, T., et al. 1998. Molecular mechanisms involved in GLUT4 translocation in muscle during insulin and contraction stimulation. Adv. Exp. Med. Biol. 441: 63-71. PMID:9781314.
13. Dong, F., Fang, C.X., Yang, X., Zhang, X., Lopez, F.L., and Ren, J. 2006. Cardiac overexpression of catalase rescues cardiac contractile dysfunction induced by insulin resistance: role of oxidative stress, protein carbonyl formation and insulin sensitivity. Diabetologia, 49: 1421-1433. doi:10.1007/s00125-006-0230-7. PMID:16586065.
14. Eaton, S. 2002. Control of mitochondrial beta-oxidation flux. Prog. Lipid Res. 41: 197-239. doi:10.1016/S0163-7827(01)00024-8. PMID:11814524.
15. Febbraio, M., and Silverstein, R.L. 2007. CD36: implications in cardiovascular disease. Int. J. Biochem. Cell Biol. 39: 2012-2030. doi:10.1016/j.biocel.2007.03.012. PMID:17466567.
16. Giles, T.D. 2003. The patient with diabetes mellitus and heart failure: at-risk issues. Am. J. Med. 115(Suppl 8A): 107S-110S. doi:10.1016/j.amjmed.2003.09.017. PMID:14678875.
17. Glatz, J.F.C., and van der Vusse, G.J. 1996. Cellular fatty acidbinding proteins: their function and physiological significance. Prog. Lipid Res. 35: 243-282. doi:10.1016/S0163-7827(96)00006-9. PMID:9082452.
18. Hulver, M.W., Berggren, J.R., Cortright, R.N., Dudek, R.W., Thompson, R.P., Pories, W.J., et al. 2003. Skeletal muscle lipid metabolism with obesity. Am. J. Physiol. Endocrinol. Metab. 284: E741-E747. PMID:12626325.
19. Inglis, S., and Stewart, S. 2006. Metabolic therapeutics in angina pectoris: history revisited with perhexiline. Eur. J. Cardiovasc. Nurs. 5: 175-184. doi:10.1016/j.ejcnurse.2006.01.001. PMID: 16469541.
20. Itani, S.I., Pories, W.J., Macdonald, K.G., and Dohm, G.L. 2001. Increased protein kinase C theta in skeletal muscle of diabetic patients. Metabolism, 50: 553-557. doi:10.1053/meta.2001.22512. PMID:11319716.
21. Kelley, D.E., Goodpaster, B., Wing, R.R., and Simoneau, J.A. 1999. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am. J. Physiol. 277: E1130-E1141. PMID:10600804.
22. Kerner, J., and Hoppel, C. 2000. Fatty acid import into mitochondria. Biochim. Biophys. Acta, 1486: 1-17. PMID:10856709.
23. Koonen, D.P.Y., Glatz, J.F.C., Bonen, A., and Luiken, J.J.F.P. 2005. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim. Biophys. Acta, 1736: 163-180. PMID:16198626.
24. Luiken, J.J.F.P., Schaap, F.G., van Nieuwenhoven, F.A., van der Vusse, G.J., Bonen, A., and Glatz, J.F.C. 1999. Cellular fatty acid transport in heart and skeletal muscle as facilitated by proteins. Lipids, 34(Suppl): S169-S175. doi:10.1007/BF02562278. PMID:10419138.
25. Luiken, J.J.F.P., Arumugam, Y., Dyck, D.J., Bell, R.C., Pelsers, M.M.A.L., Turcotte, L.P., et al. 2001. Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J. Biol. Chem. 276: 40567-40573. doi:10.1074/jbc.M100052200. PMID:11504711.
26. Luiken, J.J.F.P., Niessen, H.E., Coort, S.L.M., Hoebers, N., Coumans, W.A., Schwenk, R.W., et al. 2009. Etomoxir-induced partial CPT-I inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. Biochem. J. [Epub ahead of print.] PMID:19138173.
27. McGarry, J.D., and Brown, N.F. 1997. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244: 1-14. doi:10.1111/j.1432-1033.1997.00001.x. PMID:9063439.
28. Nicolson, G.L. 2007. Metabolic syndrome and mitochondrial function: molecular replacement and antioxidant supplements to prevent membrane peroxidation and restore mitochondrial function. J. Cell. Biochem. 100: 1352-1369. doi:10.1002/jcb.21247. PMID:17243117.
29. Nikolaidis, L.A., and Levine, T.B. 2004. Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: Friends or foes for the diabetic patient with heart failure? Cardiol. Rev. 12: 158-170. doi:10.1097/01.crd.0000102419.52594.90. PMID:15078585.
30. Ouwens, D.M., Diamant, M., Fodor, M., Habets, D.D., Pelsers, M.M.A.L., El Hasnaoui, M., et al. 2007. Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia, 50: 1938-1948. doi:10.1007/s00125-007-0735-8. PMID:17639306.
31. Randle, P.J., Garland, P.B., Newsholme, E.A., and Hales, C.N. 1965. The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann. N. Y. Acad. Sci. 131: 324-333. doi:10. 1111/j.1749-6632.1965.tb34800.x. PMID:5216972.
32. Rupp, H., Zarain-Herzberg, A., and Maisch, B. 2002. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz, 27: 621-636. doi:10. 1007/s00059-002-2428-x. PMID:12439634.
33. Saddik, M., Gamble, J., Witters, L.A., and Lopaschuk, G.D. 1993. Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. J. Biol. Chem. 268: 25836-25845. PMID:7902355.
34. Schmitz-Peiffer, C., Browne, C.L., Oakes, N.D., Watkinson, A., Chisholm, D.J., Kraegen, E.W., and Biden, T.J. 1997. Alterations in the expression and cellular localization of protein kinase C isozymes epsilon and theta are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes, 46: 169-178. doi:10.2337/diabetes.46.2.169. PMID:9000691.
35. Schmitz-Peiffer, C., Craig, D.L., and Biden, T.J. 1999. Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J. Biol. Chem. 274: 24202-24210. doi:10.1074/jbc.274.34.24202. PMID:10446195.
36. Schrauwen, P. 2007. High-fat diet, muscular lipotoxicity and insulin resistance. Proc. Nutr. Soc. 66: 33-41. doi:10.1017/S0029665107005277. PMID:17343770.
37. Schwenk, R.W., Luiken, J.J.F.P., Bonen, A., and Glatz, J.F.C. 2008. Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. Cardiovasc. Res. 79: 249-258. doi:10.1093/cvr/cvn116. PMID:18469026.
38. Shulman, G.I. 2000. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106: 171-176. doi:10.1172/JCI10583. PMID:10903330.
39. Stanley, W.C., Recchia, F.A., and Lopaschuk, G.D. 2005. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85: 1093-1129. doi:10.1152/physrev.00006.2004. PMID:15987803.
40. Szczepaniak, L.S., Victor, R.G., Orci, L., and Unger, R.H. 2007. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ. Res. 101: 759- 767. doi:10.1161/CIRCRESAHA.107.160457. PMID:17932333.
41. Taegtmeyer, H., McNulty, P., and Young, M.E. 2002. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation, 105: 1727-1733. doi:10.1161/01.CIR. 0000012466.50373.E8. PMID:11940554.
42. Thompson, A.L., and Cooney, G.J. 2000. Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance. Diabetes, 49: 1761-1765. doi:10.2337/diabetes.49.11.1761. PMID:11078441.
43. Tuunanen, H., Engblom, E., Naum, A., Någren, K., Scheinin, M., Hesse, B., et al. 2008. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation, 118: 1250-1258. doi:10.1161/CIRCULATIONAHA.108.778019. PMID:18765391.
44. Watson, R.T., and Pessin, J.E. 2006. Bridging the GAP between insulin signaling and GLUT4 translocation. Trends Biochem. Sci. 31: 215-222. doi:10.1016/j.tibs.2006.02.007. PMID:16540333.
45. Weis, B.C., Cowan, A.T., Brown, N., Foster, D.W., and McGarry, J.D. 1994. Use of a selective inhibitor of liver carnitine palmitoyltransferase I (CPT I) allows quantification of its contribution to total CPT I activity in rat heart. Evidence that the dominant cardiac CPT I isoform is identical to the skeletal muscle enzyme. J. Biol. Chem. 269: 26443-26448. PMID:7929365.
46. Wu, G., Yussman, M.G., Barrett, T.J., Hahn, H.S., Osinska, H., Hilliard, G.M., et al. 2001. Increased myocardial Rab GTPase expression: a consequence and cause of cardiomyopathy. Circ. Res. 89: 1130-1137. doi:10.1161/hh2401.100427. PMID:11739277.